Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Banzai Q4 2025 Earnings Call - Acquisition-Fueled Revenue Surge, ConnectAndSell to More Than Double Run Rate
Banzai closed 2025 with a sprint. Revenue jumped 169% for the year to $12.2 million, Q4 revenue rose 116% to $2.8 million, and gross margin expanded to roughly 82% as video and AI assets like Vidello ...
- Revenue grew 116% year-over-year in Q4 2025 to $2.8 million, and full year 2025 revenue rose 169% to $12.2 million, driven largely by acquisitions Vidello and OpenReel.
- Gross profit expanded 221% year-over-year to $10.0 million for 2025, lifting gross margin to approximately 82% from 68.6% in 2024.
- Operating expenses rose sharply to $28.4 million in 2025, primarily due to the addition of acquired businesses, contributing to a full year net loss of $22.5 million (improved from $31.5 million).
- +12 more takeaways
Barfresh Food Group Q4 2025 Earnings Call - Arps Dairy Buy Gives Control of Manufacturing, Promises Path to $200M Revenue Capacity
Barfresh closed 2025 with record revenue but squeezed margins, after a year defined by a strategic acquisition and a financing deal that retools the company's operating model. The October acquisition ...
- Record revenue for 2025: $14.2 million, up 33% year over year; Q4 2025 revenue was $5.4 million, a 94% y/y increase.
- Acquisition of Arps Dairy (Oct 2025) added a 15,000 sq ft processing plant and a 44,000 sq ft manufacturing facility in Defiance, Ohio, shifting production in-house.
- Post-acquisition production mix now roughly 90% in-house, reducing dependence on third-party co-manufacturers that previously constrained growth.
- +12 more takeaways
Edible Garden AG Q4 2025 Earnings Call - RTD push aims to pivot company to higher-margin CPG
Edible Garden spent 2025 reshaping itself from a controlled-environment produce supplier into a broader CPG player, leaning hard into ready-to-drink protein and nutraceuticals. Management reported dis...
- Distribution and retail wins: management expanded national distribution to nearly 6,000 store locations, adding more than 700 incremental retail placements in Q4, including Kroger, Weis Markets, Safeway, The Fresh Market, Busch’s, Wakefern and others.
- Q4 revenue and YoY: revenue for the three months ended December 31, 2025 was approximately $4.1 million, up from $3.9 million in Q4 2024.
- Q4 cost and gross results: cost of goods sold in Q4 was about $5.3 million versus $3.8 million a year earlier, producing a Q4 gross loss of approximately $1.2 million, compared with flat gross profit in Q4 2024.
- +12 more takeaways
Rekor Systems, Inc. FY2025 Earnings Call - Margin Inflection as Company Repositions Toward Recurring Software and Onshored Engineering
Rekor says FY2025 was a turning point, delivering modest top-line growth while cutting costs and shifting the business mix toward higher-margin software and data subscriptions. Revenue rose to $48.5 m...
- Revenue for the year ended December 31, 2025 was $48.5 million, up 5% from $46.0 million in 2024.
- Recurring revenue was $23.9 million in 2025, up 6% year-over-year, roughly a 50/50 split between recurring and equipment revenue.
- Remaining performance obligations rose to $25.9 million as of December 31, 2025, an increase of nearly 80% from a year earlier, cited as pipeline momentum into 2026.
- +13 more takeaways
Co-Diagnostics Inc. Q4 2025 Earnings Call - India TB commercialization becomes the focus as losses mount
Co-Diagnostics used the call to signal a clear pivot: India and TB diagnostics are now the most immediate commercial levers. Management highlighted CoSara’s manufacturing license, 15 locally cleared t...
- Nasdaq relisting completed, management emphasizing forward execution after the temporary listing disruption.
- Company organized growth around four pillars: clinical regulatory progress, CoSara/India strategy and alternatives, CoMira expansion in Saudi and MENA, and AI-driven platform capabilities.
- CoSara joint venture in India received CDSCO license to manufacture the PCR Pro instrument, and CoSara now services hundreds of labs with 15 PCR tests cleared locally.
- +12 more takeaways
Newton Golf Company FY2025 Earnings Call - Record Revenue Growth, But Cash Runway Tight
Newton Golf posted a startling top-line sprint in FY2025, with revenue up 136% to $8.1 million driven by a 157% surge in direct-to-consumer sales and broad adoption of its Newton Motion shaft platform...
- Revenue jumped 136% year over year to $8.1 million in FY2025, a new company record.
- Direct-to-consumer sales drove most of the gain, rising 157% to $7.4 million.
- Newton Motion shaft platform showed strong traction, with Fast Motion launched in 2025 becoming the company’s best-selling product.
- +13 more takeaways
Knightscope Q4 2025 Earnings Call - Event Risk acquisition recasts Knightscope as a managed-service play to scale into a $230B TAM
Knightscope closed 2025 with modest revenue growth, widening losses, and a cash cushion reset by financings, while announcing a strategic pivot. The company bought Event Risk to combine human guarding...
- Strategic pivot: Knightscope acquired Event Risk and intends to sell an integrated managed service combining human guards, robotics, and software, reframing the company as an Autonomous Security Force and a managed service provider.
- TAM remains $230 billion as presented on knightscope.com/america, management says the acquisition accelerates ability to penetrate that market rather than changing the TAM itself.
- Q4 2025 revenue declined ~9.8% year-over-year, driven largely by supply-chain constraints that delayed ECD product deliveries; services revenue was largely unchanged in the quarter.
- +12 more takeaways
American Shared Hospital Services Q4 2025 Earnings Call - Shift to Direct Patient Care Now Majority, But Cash and Covenant Pressure Mounts
Management says 2025 was a year of structural change, with a deliberate pivot from equipment leasing into direct patient care. The shift is real and measurable: direct patient care now generates the m...
- Company completed a strategic shift in 2025 toward a direct patient care model, which now represents the majority of total revenue.
- Total revenue for full-year 2025 was $28.1 million, roughly flat versus $28.3 million in 2024.
- Direct patient care services revenue grew 23.7% to $15.5 million in 2025, while leasing revenue declined to $12.6 million.
- +14 more takeaways
Imunon Q4 2025 Earnings Call - IMNN-001 shows unprecedented phase II OS benefit, OVATION 3 enrolling ahead of plan
Imunon opened the year riding a breakthrough phase II readout for IMNN-001, reporting a final overall survival improvement of 14.7 months in OVATION 2 and an even larger effect in the subgroup receivi...
- Final OVATION 2 phase II overall survival benefit increased to 14.7 months in the company’s final review of the trial.
- Patients who received PARP inhibitor maintenance in OVATION 2 showed a median overall survival improvement of more than two years versus control.
- OVATION 3 is a one-to-one randomized pivotal phase III that mirrors the phase II backbone, testing IMNN-001 plus standard neoadjuvant and adjuvant chemotherapy including interval debulking surgery vs standard of care alone.
- +12 more takeaways
FactSet Q2 FY2026 Earnings Call - ASV Re-acceleration and AI-Driven Data Momentum Lift Guidance
FactSet reported another quarter of re-acceleration, with organic ASV up 6.7% to $2.45 billion and Q2 revenue rising 7.1% to $611 million. Management is arguing that the company is not being displaced...
- Organic ASV accelerated to 6.7% in Q2, reaching $2.45 billion, marking the fourth consecutive quarter of acceleration.
- Q2 revenue grew 7.1% year-over-year to $611 million; adjusted diluted EPS was $4.46, up 4% from a year ago.
- FactSet raised fiscal 2026 ASV guidance to $130 million–$160 million (approx. 5.4%–6.7% growth) and nudged GAAP revenue midpoint up by $25 million.
- +12 more takeaways